WHO panel proposes new global registry for all CRISPR human experiments
By Jon Cohen,
Science
| 03. 19. 2019
There’s an “urgent need” to create a transparent global registry that would list all experiments related to human genome editing, an expert committee convened to advise the World Health Organization (WHO) said today. The international committee of 18 researchers and bioethicists, which met in Geneva, Switzerland, over the past 2 days, also agreed with the widespread consensus that it would be “irresponsible at this time for anyone to proceed with clinical applications of human germline genome editing.”
The committee stopped short, however, of endorsing the call for a “moratorium” on human germline editing issued last week by prominent group of researchers in a Nature commentary. “I don’t think a vague moratorium is the answer to what needs to be done,” said Margaret Hamburg, a co-chair of the WHO committee who formerly headed the U.S. Food and Drug Administration and now works with the U.S. National Academy of Medicine in Washington, D.C., during a teleconference for the media today. Several other high-profile statements and reports on genome editing have also avoided using the word “moratorium,” although they have similarly emphasized...
Related Articles
By Emily Mullin, Wired | 04.23.2026
A STARTUP OUT of Utah, Paterna Biosciences, says it has successfully grown functional human sperm in a lab and used the sperm to make visibly healthy-looking embryos. The technique could eventually help men with certain types of infertility have biological children...
By Julianna LeMieux, Genetic Engineering & Biotechnology News | 04.14.2026
Twenty years ago, Sven Bocklandt, PhD, sought to create a hypoallergenic cat. He had the genetic engineering chops to do it, but the embryology was beyond his capabilities. At a small animal genetic engineering conference, known as TARC (Transgenic Animal...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...